Control Rx
ApprovedSmall molecule
Control Rx is one of 117 small molecule programs targeting Angina Pectoris. It is currently in Approved.
4
Indications
8
Total Trials
1
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Control Rx
TTanta University
Approved
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
LCZ696
NovartisPreclinical
Monoferric
PPharmacosmos A/S
Preclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Savaysa
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure2 trials
Total Knee Arthroplasty1 trial
The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty
Completed·—·N/A·NCT05514197·73 enrolled
Sintilimab1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Control Rx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTanta University